NEW YORK (GenomeWeb News) – DNAVision said yesterday that it will offer Ipsogen’s new MapQuant Dx Genomic Grade test through its central lab services in Europe.
The MapQuant Dx is a molecular diagnostic, gene expression-based test that measures tumor grade, risk of metastasis, and chemotherapy response, among breast cancer patients. Ipsogen launched the test last week.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

360Dx reports that the US Centers for Medicare & Medicaid Services would cover next-generation sequencing-based cancer panel tests.

The Washington Post reports that a meteorologist is being considered as presidential science and technology advisor.

In PNAS this week: precision medicine strategy to screen for disease risk, genome evolution in Haemophilus influenzae, and more.

Researchers have developed a PCR-based assay to gauge whether manatees are present in waters.